Professionals
more
professional-bg-img

Dan Constantinescu

Associate, Intellectual Property
New York New York dconstantinescu@willkie.com dconstantinescu@willkie.com +1 212 728 8549 +1 212 728 8549

Dan Constantinescu is an associate in the Intellectual Property Department. With a scientific background in the biological sciences, Dan has represented major biopharmaceutical and biotechnology companies in various aspects of patent litigation, including BPCIA and Hatch-Waxman litigation, as well as inter partes review proceedings before the U.S. Patent and Trademark Office. He also has experience advising clients regarding due diligence, freedom-to-operate, and patentability studies for life science products, including small molecules, therapeutic proteins, and antibody production technologies.

Experience

Dan is a member of the New York Intellectual Property Law Association and the New York State Bar Association.

  • Genentech v. Pfizer (bevacizumab) – Currently representing Pfizer in BPCIA litigation concerning Pfizer’s Avastin biosimilar product.
  • Pfizer v. Roche – Currently representing Pfizer in IPR proceeding concerning patent related to recombinant antibody technology.
  • Genentech v. Hospira (bevacizumab) – Currently representing Hospira in Federal Circuit appeal after obtaining favorable decision in IPR proceeding concerning patent related to Avastin.
  • Genentech v. Pfizer (trastuzumab) – Represented Pfizer in BPCIA litigation concerning Pfizer’s Herceptin biosimilar product.
  • Amgen v. Hospira (erythropoietin) – Represented Hospira in one of the first BPCIA litigations concerning Hospira’s Epogen biosimilar product.
  • Hospira v. Genentech (bevacizumab) – Represented Hospira in successful IPR proceeding concerning patent related to Avastin.
  • Hospira v. Euroheath International – Represented Hospira in patent litigation concerning Hospira’s branded Precedex product. 
  • Takeda v. Actavis (bupropion and naltrexone) – Represented Actavis in patent litigation concerning Actavis’s Contrave generic product.
  • Sanofi v. Actavis (cabazitaxel) – Represent Actavis in patent litigation concerning Activis’s Jevtana generic product.

Credentials

Education

University of California College of the Law, San Francisco, J.D., 2012 University of Pittsburgh, PhD, 2008 Haverford College, B.S., 1999

Bar Admissions

New York, 2013

Court Admissions

United States District Court, Southern District of New York, 2014